VALLEY COTTAGE, New York, May 4, 2017 /PRNewswire/ --
High costs involved in the research & development (R&D) of obesity drugs, coupled with limited financial support, are collectively a great challenge for adoption of obesity management solutions. Additionally, long gestation time needed for R&D activities, and the inclusion of clinical trials required to test these drugs hikes the expenditure significantly. Considering this scenario, manufacturers are being cautious while seeking better return on investments. In the long run, risks and limitations posed by the high development costs of obesity drugs are likely to impede the growth of the global obesity management market.
Future Market Insights' latest publication estimates that the global market for obesity management will showcase an average growth during the forecast period, 2017-2027. In this period, the market is estimated to grow from US$ 641.6 Mn in 2016 to US$ 1,078.9 by 2027-end, representing a value CAGR of 4.9%. Between 2017 and 2027, the global obesity management market is poised to witness an incremental $ opportunity of over US$ 400 Mn.
Request for Sample Report with Table of Contents: http://www.futuremarketinsights.com/reports/sample/rep-gb-587
In addition the high costs for developing obesity management drugs, the market is also expected to witness restraints from poor healthcare infrastructure in emerging markets. Stringent laws imposed upon drug manufacturers are also impacting the market's growth. These laws are becoming more ambiguous, resulting into a slow-down in drug production. Moreover, studies revealing side effects of obesity management drugs are also causing major disturbance among regulatory bodies and manufacturers. GlaxoSmithKline plc., VIVUS, Inc., Novo Nordisk A/S, Arena Pharmaceuticals, Inc., F. Hoffmann La Roche Ltd., and Orexigen, Therapeutics, Inc. are companies profiled in the report as leading participants of global obesity management market.
A regional analysis of global obesity management market, compiled in the report, projects that North America's share on global revenues will surpass 33% towards the end of 2027. North America is anticipated to emerge as the largest market for obesity management in the world. Western Europe will also be at the forefront, bringing in an estimated US$ 222 Mn in revenues by 2027-end. Across different regions in the world, a majority of obesity management drugs will be distributed through hospital pharmacies. With more than 50% share in global revenues, hospital pharmacies will remain the largest distribution channel for obesity management drugs throughout the forecast period.
Preview Analysis on Global Obesity Management Market Segmentation By Treatment Type - Drug (Bupropion and Naltrexone, Orlistat, Lorcaserin, Phentermine and Topiramate, Liraglutide), Surgery (Gastric Bypass, Adjustable Gastric Banding, Gastric Sleeve, Duodenal Switch, Intragastric Balloon Treatment); By Distribution Channel - Hospitals, Speciality Clinics, Ambulatory Surgical Centres, Retail Pharmacies: http://www.futuremarketinsights.com/reports/obesity-management-market
In terms of surgery, the global demand for obesity management drugs is primarily concentrated towards treatments namely, gastric bypass surgery and gastric sleeve surgery. In addition to this, the report also projects that over one-third of global obesity management revenues will be accounted by global sales of liraglutide drugs. Demand for phentermine and topiramate drugs will also gain traction, registering revenue growth at 7% CAGR. Nonetheless, fastest revenue growth will be recorded by global sales of bupropion and naltrexone drugs, revenues from which will surpass US$ 100 Mn by end of 2027.
More from FMI's Cutting-edge Intelligence:
- Balloon Catheter Market Segmentation By Product - Normal, Cutting, Scoring, Drug Eluting, and Stent Graft Balloon Catheter; By Disease Indication - Coronary Artery Disease, Peripheral Vascular Disease; By Raw Material - Polyurethane, Nylon; By End User - Hospitals, Public Hospitals, Private Hospitals, Ambulatory Surgical Centres, Cardiac Catheterisation Laboratories: http://www.futuremarketinsights.com/reports/balloon-catheter-market
- Paediatric Vaccine Market Segmentation By Technology - Live Or Attenuated Vaccine, Inactivated Or Killed Vaccine, Toxoid Vaccine, Conjugate Vaccine and Subunit Vaccine; By Indication - Pneumococcal Conjugate Vaccine, DTP Vaccine, Influenza, Meningococcal Vaccine, Polio Vaccine, Rotavirus Vaccine, MMR Vaccine and Varicella Virus Vaccine; By End User - Hospital Pharmacies, Retail Pharmacies and Institutional Health Centres; By Vaccine Type - Monovalent Vaccines and Multivalent Vaccines: http://www.futuremarketinsights.com/reports/pediatric-vaccines-market
- Widefield Imaging Systems Market Segmentation By Indication - Diabetic Retinopathy, Retinopathy of Prematurity, Pediatric Retinal Diseases, Retinal Vein Occlusion, Ocular Oncology, Uveitis, Chorioretinal Diseases, Glaucoma; By Component - Instruments, Software (Image Viewing & Data Analysis and Interpretation Software); By Modality - Standalone, Portable; By End User - Specialty Clinics, Hospitals, Ambulatory Surgical Centres: http://www.futuremarketinsights.com/reports/wide-field-imaging-systems-market
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights and an aerial view of the competitive framework and future market trends.
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
T (UK): + 44 (0) 20-7692-8790
Press Office: Press@futuremrketinsights.com
SOURCE Future Market Insights